<DOC>
	<DOCNO>NCT02000622</DOCNO>
	<brief_summary>This open label , randomise , control , multi-centre phase III study ass efficacy safety single agent olaparib v standard care base physician 's choice capecitabine , vinorelbine eribulin metastatic breast cancer patient gBRCA 1/2 mutation .</brief_summary>
	<brief_title>Assessment Efficacy Safety Olaparib Monotherapy Versus Physicians Choice Chemotherapy Treatment Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Germline mutation BRCA1 BRCA2 predict deleterious suspect deleterious . Histologically cytologically confirm breast cancer evidence metastatic disease . Prior therapy anthracycline taxane either adjuvant metastatic setting . Prior platinum allow long breast cancer progression occur treatment give adjuvant/neoadjuvant set least 12 month last dose study entry elapse . ER/PR breast cancer positive patient must receive progress least one endocrine therapy ( adjuvant metastatic ) , disease treat physician believe inappropriate endocrine therapy . ECOG performance status 01 . Adequate bone marrow , kidney liver function . Prior treatment PARP inhibitor . Patients HER2 positive disease . More 2 prior line chemotherapy metastatic breast cancer . Untreated and/or uncontrolled brain metastasis . Prior malignancy unless curatively treat diseasefree &gt; 5 year prior study entry . Prior adequately treat nonmelanoma skin cancer , situ cancer cervix , DCIS stage I grade 1 endometrial cancer allow . Known HIV ( Human Immunodeficiency Virus ) infection . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Olaparib</keyword>
	<keyword>BRCA</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>HER2</keyword>
	<keyword>chemotherapy</keyword>
</DOC>